Clinical efficacy and cost–effectiveness of rosuvastatin

References

• American Heart Association. Heart Disease and Stroke Statistics—2006 Update. American Heart Association, Dallas, Texas (2006).
   Google Scholar
• Rosamond WD, Chambless LE, Folsom AR et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N. Engl. J. Med.339(13), 861–867 (1998).
   PubMed Web of Science ®Google Scholar
• Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation110(5), 522–527 (2004).
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care16(2), 434–444 (1993).
   PubMed Web of Science ®Google Scholar
• Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br. J. Med.308(6925), 367–372 (1994).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344(8934), 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al; for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med.335(14), 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med.339(19), 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al; for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med.333(20), 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al; for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA279(20), 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Bairey Merz CN et al; for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Olsson AG, Istad H, Luurila O et al; on behalf of the Rosuvastatin Investigators Group. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart J.144(6), 1044–1051 (2002).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al; for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol.92(2), 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW, for the STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr. Med. Res. Opin.19(8), 689–698 (2003).
   PubMed Web of Science ®Google Scholar
• Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am. J. Cardiol.91(Suppl. 5A), 3C–10C (2003).
   PubMed Web of Science ®Google Scholar
• Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am. J. Cardiol.91(1), 33–41 (2003).
   PubMed Web of Science ®Google Scholar
• Bullano MF, Wertz DA, Yang GW et al. Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting. Pharmacotherapy26(4), 469–478 (2006).
   PubMed Web of Science ®Google Scholar
• Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparing effectiveness of rosuvastatin with other statins in reducing low density lipoprotein cholesterol (LDL-C) in the elderly patient population: results from routine clinical practice setting. Poster presented at the American Heart Association 7th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke, Washington, DC (May 7–8, 2006).
   Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Miller PSJ, Smith DG, Jones P. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US analysis of the STELLAR trial). Am. J. Cardiol.95(11), 1314–1319 (2005).
   PubMedGoogle Scholar
• Chong PH, Varner D. Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. Pharmacotherapy25(2), 270–278 (2005).
   PubMedGoogle Scholar
• Palmer SJ, Brady AJ, Ratcliffe AE. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Int. J. Clin. Pract.57(9), 792–800 (2003).
   PubMed Web of Science ®Google Scholar
• Hirsch M, O’Donnell JC, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur. J. Cardiovasc. Prev. Rehabil.12(1), 18–28 (2005).
   PubMed Web of Science ®Google Scholar
• Hirsch M, O’Donnell J, Olsson A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int. J. Cardiol.104(3), 251–256 (2005).
   PubMedGoogle Scholar
• Miller PSJ, Leiter LA, Davies A, Sosef F. Rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolaemia: economic analysis of the POLARIS study. Atheroscler. Suppl.6(1), 114 (2005). Abstract W16-P-055.
   Google Scholar
• Davies A, Hutton J, O’Donnell J, Kingslake S. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK. Br. J. Cardiol.13(3), 196–202 (2006).
   Google Scholar
• Benner JS, Smith TW, Klingman D et al. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health8(6), 618–628 (2005).
   PubMed Web of Science ®Google Scholar
• Brown WV, Bays HE, Hassman DR et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J.144(6), 1036–1043 (2002).
   PubMed Web of Science ®Google Scholar
• Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin. Drug Saf.3(6), 547–557 (2004).
   PubMedGoogle Scholar
• Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol.92(Suppl. 4B), 23K–29K (2003).
   PubMed Web of Science ®Google Scholar
• Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology102(1), 52–60 (2004).
   PubMed Web of Science ®Google Scholar
• Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet.41(5), 343–370 (2002).
   PubMed Web of Science ®Google Scholar
• Cziraky MJ, Willey VJ, McKenney JM et al. Statin safety: an assessment using an administrative claims database. Am. J. Cardiol.97(Suppl. 8A), 61C–68C (2006).
   PubMed Web of Science ®Google Scholar
• Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther.78(2), 154–167 (2005).
   PubMed Web of Science ®Google Scholar
• Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther.68(6), 592–597 (2000).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Gandhi SK, Ming EE et al. Concomitant prescribing rates of statins and cytochrome P450 3A4 inhibitors and inducers in real-world clinical practice. Presented at the 22nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Lisbon, Portugal (2006).
   Google Scholar
• Takeda M, Noshiro R, Tojo A et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. Eur. J. Pharmacol.483(2–3), 133–138 (2004).
   PubMed Web of Science ®Google Scholar
• Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother.35(9), 1096–1107 (2001).
   Google Scholar
• Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J. Manag. Care Pharm.9(6), 544–551 (2003).
   PubMedGoogle Scholar
• Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am. J. Manag. Care12(1), 21–28 (2006).
   PubMed Web of Science ®Google Scholar
• Landmesser U, Bahlmann F, Mueller M et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation111(18), 2356–2363 (2005).
   PubMed Web of Science ®Google Scholar
• Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy: the role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation107(25), 3124–3128 (2003).
   PubMed Web of Science ®Google Scholar
• Ballantyne C, Sosef F, Duffield E, on behalf of the EXPLORER Study Investigators. Efficacy and safety of rosuvastatin plus ezetimibe in high-risk patients: results from the EXPLORER study. Poster presented at the XIV International Symposium on Atherosclerosis, Rome, Italy (2006).
   Google Scholar
• Stafford RS, Blumenthal D, Pasternak RC. Variations in cholesterol management practices of U.S. physicians. J. Am. Coll. Cardiol.29(1), 139–146 (1997).
   PubMedGoogle Scholar
• Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA, for the National Registry of Myocardial Infarction 3 participants. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation103(1), 38–44 (2001).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med.160(4), 459–467 (2000).
   PubMed Web of Science ®Google Scholar
• Durrington P. The human and economic costs of undertreatment with statins. Int. J. Clin. Pract.56(5), 357–368 (2002).
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programmme. Eur. Heart J.22(7), 554–572 (2001).
   PubMed Web of Science ®Google Scholar
• DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994–2001: a case of ageism but not of sexism? Heart89(4), 417–421 (2003).
   PubMed Web of Science ®Google Scholar